Stock Financial Ratios


RTTR / Ritter Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price0.34
Volume451,300.00
Market Cap ($M)5.46
Enterprise Value ($M)-2.27
Book Value ($M)4.10
Book Value / Share0.46
Price / Book4.54
NCAV ($M)4.10
NCAV / Share0.46
Price / NCAV1.31
Income Statement (mra) ($M)
Revenue0.00
EBITDA-18.45
Net Income-18.38
Balance Sheet (mrq) ($M)
Cash & Equivalents3.56
Cash / Share0.40
Assets4.16
Liabilities2.96
Quick Ratio2.30
Current Ratio2.30
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-4.48
Return on Assets (ROA)-2.54
Return on Equity (ROE)-4.48
Identifiers and Descriptors
CUSIP767836109
Central Index Key (CIK)1460702
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Share Statistics
Common Shares Outstanding (M)49.51
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Cash And Equivalents Per Share0.40
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Liabilities Current Per Share0.33
Retained Earnings Per Share-5.68
Minority Interest Per Share0.00
Inventory Work In Progress Per Share0.00
Long Term Debt Per Share0.00
Cash Per Share0.40
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Debt Per Share0.00
Liabilities And Stock Equity Per Share0.46
Inventory Per Share0.00
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Liabilities Per Share0.33
Goodwill Per Share0.00
Assets Per Share0.46
Property Plant And Equipment Net Per Share0.00
Equity Per Share0.13
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Additional Paid In Capital Per Share5.82
Inventory Raw Materials Per Share0.00
Assets Current Per Share0.42

Stock Research Report

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Ritter Pharmaceuticals is advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have a meaningful impact on a patient’s health. The company completed a Phase 2a clinical trial of its leading product candidate, RP-G28, an orally administered, high purity oligosaccharide in November 2011.

The company completed a Phase 2b/3 multi-center, randomized, double-blind, placebo-controlled, parallel group trial of RP-G28 in October 2016. The purpose of the trial was to evaluate the safety, efficacy and tolerability of two dosing regimens of RP-G28 in patients with moderate to severe lactose intolerance symptoms. Enrollment was initiated in March 2016 and completed in August 2016, achieving its projected enrollment time pe...

Click for full article

Related News Stories

Stocks To Watch: Retailers Make Final Holiday Push

2017-12-23 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn on the e-mail alert on to receive this article in your inbox every Saturday morning. (664-4)

Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys

2017-12-20 zacks
Chicago, IL – Dec 20, 2017 - Stocks in this week’s article include: BioTime Inc. (BTX - Free Report) , Ritter Pharmaceuticals Inc. (RTTR - Free Report) , Organovo Holdings Inc. (ONVO - Free Report) , American Superconductor Corp. (AMSC - Free Report) and Stratasys Ltd. (SSYS - Free Report) . (116-0)

Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys

2017-12-05 zacks
Chicago, IL – Dec 5, 2017 - Stocks in this week’s article include: BioTime Inc. (BTX - Free Report) , Ritter Pharmaceuticals Inc. (RTTR - Free Report) , Organovo Holdings Inc. (ONVO - Free Report) , Signal Genetics Inc. (MGEN - Free Report) and Stratasys Ltd. (SSYS - Free Report) . (200-2)

Keep Faith in Rising P/E: Play 5 Top-Ranked Stocks

2017-12-04 zacks
Generally, investors love stocks with a low price-to-earnings (P/E) ratio. The general perception is that the lower the P/E, the higher will be the value of the stock. The simple logic that a stock’s current market price does not justify (is not equivalent to) its higher earnings and therefore has room to run is behind investors’ inclination toward low P/E stocks. (121-0)

Garmin, Fabrinet, Salesfore.com, Hewlett Packard Enterprise and Deere & Company highlighted as Zacks Bull and Bear of the Day

2017-11-20 zacks
Chicago, IL – November 20, 2017 – Zacks Equity Research highlights Garmin Ltd (GRMN - Free Report) as the Bull of the Day and Fabrinet (FN - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Salesfore.com (CRM - Free Report) , Hewlett Packard Enterprise (HPE - Free Report) and Deere & Company (DE - Free Report) . (96-2)

CUSIP: 767836109